# Caicun Zhou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/caicun-zhou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,309 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 119 |
| Last Known Institution | Tongji University |
| OpenAlex ID | https://openalex.org/A5006820907 |
| ORCID iD | https://orcid.org/0000-0002-2246-5541 |
| Works | 242 |

## Researcher papers

Showing 12 of 17.

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial](https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6](https://scholariq.org/papers/clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung/)
- [Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial](https://scholariq.org/papers/afatinib-versus-placebo-for-patients-with-advanced-metastatic-non-small-cell/)
- [First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study](https://scholariq.org/papers/first-line-erlotinib-versus-gemcitabine-cisplatin-in-patients-with-advanced-egfr/)
- [Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients](https://scholariq.org/papers/investigating-novel-resistance-mechanisms-to-third-generation-egfr-tyrosine/)
- [Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial](https://scholariq.org/papers/icotinib-versus-gefitinib-in-previously-treated-advanced-non-small-cell-lung/)
- [Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Tongji University](https://scholariq.org/institutions/tongji-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.